FORM 4

obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     HANTSON LUDWIG						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS, INC. [ ALXN ]									(Check all app		tor		10% C	
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BLVD					3. Date of Earliest Transaction (Month/Day/Year) 02/28/2020										below)	)	EO	below)		
(Street) BOSTON MA 02210  (City) (State) (Zip)					- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	le I - N	on-Deriv	<i>r</i> ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or	Ben	efici	ally O	wne	d			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/						Execution Date,					es Acquired (A) or Of (D) (Instr. 3, 4 aı			ind 5) Secur Benet		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A)	or	Price	т	ransad	ction(s) 3 and 4)			(111501. 4)
Common Stock, par value \$.0001 per share 02/28/20						20		Α		44,201(1)	) ]	A	\$0		202,266		D			
Common Stock, par value \$.0001 per share 03/02/20						)20		F		8,406(2)	]	D	\$90.54(3)		193,860		D			
		Та	able II								osed of, convertib					ned				
1. Title of Derivative Security (Instr. 3)	or Exercise Price of Derivative Security (Month/Day/Year) if any (Month/Day/Ye			4. Transa Code ( 8)	Instr.	nstr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expiral (Month	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amour or Numbe of Title Shares		nstr. 3	8. Price Derivat Securii (Instr. !	tive (1)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	: ct (D) direct	Beneficial Ownership (Instr. 4)			

## **Explanation of Responses:**

- 1. Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date.
- 2. This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
- 3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$90.48 \$92.26. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

## Remarks:

/s/ Douglas Barry, Attorney-in-Fact for Ludwig Hantson

03/03/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.